Q-omics provides the consensus-scored PMS2P12 profile across patient tissues and cancer cell-line models. PMS2P12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PMS2P12 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, PMS2P12 RNA expression shows 5,925 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, and STAD as cancer lineages where PMS2P12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PMS2P12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PMS2P12 survival associations across molecular data types. PMS2P12 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PMS2P12 RNA expression–survival associations across cancer types. High PMS2P12 expression shows unfavorable associations in KICH, ACC, UVM and CESC, but favorable associations in THCA and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for PMS2P12 RNA expression.
This table summarizes PMS2P12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for PMS2P12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PMS2P12 shows lower tumor expression in KICH and KIRP and higher tumor expression in LUAD, LIHC, CHOL and KIRC. The KICH box plot shows higher PMS2P12 RNA expression in normal versus tumor tissue (log2 FC = −0.697, t-test p < 0.001).
This table shows molecular features associated with PMS2P12 in patient tissues and cancer cell lines. In patient samples, PMS2P12 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
